Intravenous nitroglycerin. A review of pharmacology, indications, therapeutic effects and complications

N. S. Hill, E. M. Antman, L. H. Green, Joseph S Alpert

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Since the first description of nitroglycerin (NTG) as an antianginal agent one century ago, its use for this indication has become widely accepted. Recently, other uses have been proposed, including therapy of congestive heart failure, reduction of infarct size, treatment of heart failure following acute myocardial infarction (MI), and blood pressure reduction during either coronary artery bypass or general surgery. For many years, the only route for administration of nitroglycerin was sublingual, but in recent years other routes have gained acceptance, including cutaneous ointment, sustained-release oral forms, and even an inhalation aerosol. More recently, attention has focused on the intravenous (IV) route, with proponents extolling the ease and predictability of administration that make intravenous nitroglycerin (IVNTG) a valuable tool in a wide variety of clinical situations. Relatively few clinical studies and little critical commentary have been published on the use of IVNTG. We review critically recent pertinent literature and make general recommendations regarding current use.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalChest
Volume79
Issue number1
StatePublished - 1981
Externally publishedYes

Fingerprint

Nitroglycerin
Therapeutic Uses
Pharmacology
Heart Failure
Ointments
Aerosols
Treatment Failure
Coronary Artery Bypass
Intravenous Administration
Inhalation
Myocardial Infarction
Blood Pressure
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Intravenous nitroglycerin. A review of pharmacology, indications, therapeutic effects and complications. / Hill, N. S.; Antman, E. M.; Green, L. H.; Alpert, Joseph S.

In: Chest, Vol. 79, No. 1, 1981, p. 69-76.

Research output: Contribution to journalArticle

Hill, N. S. ; Antman, E. M. ; Green, L. H. ; Alpert, Joseph S. / Intravenous nitroglycerin. A review of pharmacology, indications, therapeutic effects and complications. In: Chest. 1981 ; Vol. 79, No. 1. pp. 69-76.
@article{fa22ab74f5304ddcb260ccbc8874038e,
title = "Intravenous nitroglycerin. A review of pharmacology, indications, therapeutic effects and complications",
abstract = "Since the first description of nitroglycerin (NTG) as an antianginal agent one century ago, its use for this indication has become widely accepted. Recently, other uses have been proposed, including therapy of congestive heart failure, reduction of infarct size, treatment of heart failure following acute myocardial infarction (MI), and blood pressure reduction during either coronary artery bypass or general surgery. For many years, the only route for administration of nitroglycerin was sublingual, but in recent years other routes have gained acceptance, including cutaneous ointment, sustained-release oral forms, and even an inhalation aerosol. More recently, attention has focused on the intravenous (IV) route, with proponents extolling the ease and predictability of administration that make intravenous nitroglycerin (IVNTG) a valuable tool in a wide variety of clinical situations. Relatively few clinical studies and little critical commentary have been published on the use of IVNTG. We review critically recent pertinent literature and make general recommendations regarding current use.",
author = "Hill, {N. S.} and Antman, {E. M.} and Green, {L. H.} and Alpert, {Joseph S}",
year = "1981",
language = "English (US)",
volume = "79",
pages = "69--76",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Intravenous nitroglycerin. A review of pharmacology, indications, therapeutic effects and complications

AU - Hill, N. S.

AU - Antman, E. M.

AU - Green, L. H.

AU - Alpert, Joseph S

PY - 1981

Y1 - 1981

N2 - Since the first description of nitroglycerin (NTG) as an antianginal agent one century ago, its use for this indication has become widely accepted. Recently, other uses have been proposed, including therapy of congestive heart failure, reduction of infarct size, treatment of heart failure following acute myocardial infarction (MI), and blood pressure reduction during either coronary artery bypass or general surgery. For many years, the only route for administration of nitroglycerin was sublingual, but in recent years other routes have gained acceptance, including cutaneous ointment, sustained-release oral forms, and even an inhalation aerosol. More recently, attention has focused on the intravenous (IV) route, with proponents extolling the ease and predictability of administration that make intravenous nitroglycerin (IVNTG) a valuable tool in a wide variety of clinical situations. Relatively few clinical studies and little critical commentary have been published on the use of IVNTG. We review critically recent pertinent literature and make general recommendations regarding current use.

AB - Since the first description of nitroglycerin (NTG) as an antianginal agent one century ago, its use for this indication has become widely accepted. Recently, other uses have been proposed, including therapy of congestive heart failure, reduction of infarct size, treatment of heart failure following acute myocardial infarction (MI), and blood pressure reduction during either coronary artery bypass or general surgery. For many years, the only route for administration of nitroglycerin was sublingual, but in recent years other routes have gained acceptance, including cutaneous ointment, sustained-release oral forms, and even an inhalation aerosol. More recently, attention has focused on the intravenous (IV) route, with proponents extolling the ease and predictability of administration that make intravenous nitroglycerin (IVNTG) a valuable tool in a wide variety of clinical situations. Relatively few clinical studies and little critical commentary have been published on the use of IVNTG. We review critically recent pertinent literature and make general recommendations regarding current use.

UR - http://www.scopus.com/inward/record.url?scp=0019363464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019363464&partnerID=8YFLogxK

M3 - Article

C2 - 6778665

AN - SCOPUS:0019363464

VL - 79

SP - 69

EP - 76

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -